TOI/TOIIW Reports Quarter-End Financials; Exhibit 99.1 Included

Rhea-AI Filing Summary

The Oncology Institute, Inc. furnished a press release that discloses its financial results and additional financial information for the three months ended June 30, 2025. The filing states the press release is provided as Exhibit 99.1 and clarifies that the information is being furnished rather than filed under the Exchange Act, limiting certain legal liabilities. The report lists the company’s registered securities (common stock: TOI; redeemable warrants: TOIIW) on Nasdaq and identifies the company as an emerging growth company. No detailed financial tables or specific line-item results are included in the 8-K text itself; readers must refer to Exhibit 99.1 for the full figures.

Positive

• Press release furnished as Exhibit 99.1 announcing financial results for the three months ended June 30, 2025
• Disclosure clarity: the company states the information is furnished and not filed, clarifying legal treatment
• Registered securities listed (TOI common stock and TOIIW warrants) and exchange (Nasdaq) are specified

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine earnings disclosure furnished via press release; no new material amendment in the 8-K text itself.

The filing serves primarily to distribute the company’s quarter-end results to investors by furnishing a press release as Exhibit 99.1. Because the 8-K explicitly states the information is furnished and not filed, it limits Section 18 liabilities while still providing market access to quarter-end performance. The 8-K text does not include numerical results or commentary on drivers, so material assessment requires review of Exhibit 99.1.

Corporate Governance Expert

TL;DR: Standard disclosure practice observed; governance and disclosure formality maintained.

The report follows customary disclosure procedure by furnishing an earnings press release and identifying exhibits. The document confirms registered securities and emerging growth company status which affects disclosure flexibility. There are no governance actions, executive changes, or material transactions disclosed within the 8-K text itself.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001799191 0001799191 2025-08-13 2025-08-13 0001799191 TOI:CommonStockParValue0.0001Member 2025-08-13 2025-08-13 0001799191 TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

Form 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  August 13, 2025

___________________________________

THE ONCOLOGY INSTITUTE, INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware		001-39248		84-3562323
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

18000 Studebaker Road, Suite 800, Cerritos, CA		90703
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:  (562) 735-3226

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		TOI		The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share		TOIIW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.

Item 2.02. Results of Operations and Financial Condition

On August 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein.

The information contained in Item 2.02 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by The Oncology Institute, Inc. on August 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2025	THE ONCOLOGY INSTITUTE, INC.
	By:	/s/ Robert Carter
	Name:	Robert Carter
	Title:	Chief Financial Officer

FAQ

What did The Oncology Institute (TOIIW) disclose in this 8-K?

The company furnished a press release announcing its financial results for the three months ended June 30, 2025, provided as Exhibit 99.1.

Is the information in this 8-K considered filed with the SEC?

No. The filing states the information and Exhibit 99.1 are being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

Where can I find the detailed financial figures referenced in the 8-K?

The detailed figures and additional financial information are contained in the press release attached as Exhibit 99.1 to this report.

Which securities of The Oncology Institute are registered and what are their tickers?

Common stock is registered under the ticker TOI and redeemable warrants under TOIIW, both on The Nasdaq Stock Market.

Does the 8-K indicate The Oncology Institute is an emerging growth company?

Yes, the document indicates the registrant has checked the box identifying it as an emerging growth company.